Serracino-Inglott A - Search Results

1

The changing landscape of treatment options in childhood acute lymphoblastic leukaemia.

Micallef B, Nisticò R, Sarac SB, Bjerrum OW, Butler D, Sammut Bartolo N, Serracino-Inglott A, Borg JJ. Micallef B, et al. Among authors: serracino inglott a. Drug Discov Today. 2022 May;27(5):1483-1494. doi: 10.1016/j.drudis.2022.01.002. Epub 2022 Jan 7. Drug Discov Today. 2022. PMID: 35007767 Review.

2

Comment on: "EU's new pharmacovigilance legislation: considerations for biosimilars".

Borg JJ, Serracino-Inglott A, Azzopardi LM, Schneider CK. Borg JJ, et al. Drug Saf. 2014 Feb;37(2):123-4. doi: 10.1007/s40264-013-0128-5. Drug Saf. 2014. PMID: 24338043 No abstract available.

3

Could EU herbal monographs contribute to Malta's treatment armamentarium?

Micallef B, Attard E, Serracino-Inglott A, Borg JJ. Micallef B, et al. Phytomedicine. 2015 Mar 15;22(3):400-5. doi: 10.1016/j.phymed.2015.01.005. Epub 2015 Feb 26. Phytomedicine. 2015. PMID: 25837278

4

Designing a national combined reporting form for adverse drug reactions and medication errors.

Tanti A, Serracino-Inglott A, Borg JJ. Tanti A, et al. East Mediterr Health J. 2015 Jun 9;21(4):246-55. doi: 10.26719/2015.21.4.246. East Mediterr Health J. 2015. PMID: 26077519 Free article.

5

European Union pharmacovigilance capabilities: potential for the new legislation.

Borg JJ, Tanti A, Kouvelas D, Lungu C, Pirozynski M, Serracino-Inglott A, Aislaitner G. Borg JJ, et al. Ther Adv Drug Saf. 2015 Aug;6(4):120-40. doi: 10.1177/2042098615591802. Ther Adv Drug Saf. 2015. PMID: 26301067 Free PMC article. Review.

6

Multimodal management as requirement for the clinical use of anticachexia drugs - a regulatory and a clinical perspective.

Borg JJ, Anker SD, Rosano G, Serracino-Inglott A, Strasser F. Borg JJ, et al. Curr Opin Support Palliat Care. 2015 Dec;9(4):333-45. doi: 10.1097/SPC.0000000000000176. Curr Opin Support Palliat Care. 2015. PMID: 26509859 Review.

7

A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.

Tanti A, Micallef B, Serracino-Inglott A, Borg JJ. Tanti A, et al. Expert Opin Drug Saf. 2017 Jan;16(1):65-76. doi: 10.1080/14740338.2017.1247806. Epub 2016 Oct 24. Expert Opin Drug Saf. 2017. PMID: 27732110 Review.

8

Changing paradigms in bioequivalence trials submitted to the EMA for evaluation - A clinical and regulatory perspective.

Refalo N, Chetcuti D, Tanti A, Serracino-Inglott A, Borg JJ. Refalo N, et al. Saudi Pharm J. 2017 Feb;25(2):280-289. doi: 10.1016/j.jsps.2016.07.005. Epub 2016 Jul 29. Saudi Pharm J. 2017. PMID: 28344480 Free PMC article.

9

Pharmaceutical issues during the review of European Marketing Authorisation Applications in Malta.

Chetcuti M, Serracino-Inglott A, Flores G, Borg JJ. Chetcuti M, et al. Pharm Dev Technol. 2018 Jul;23(6):561-572. doi: 10.1080/10837450.2017.1360348. Epub 2017 Aug 7. Pharm Dev Technol. 2018. PMID: 28758819

10

Opinions of Maltese doctors and pharmacists on medication errors.

Tanti A, Camilleri M, Borg AA, Micallef B, Flores G, Serracino-Inglott A, Borg JJ. Tanti A, et al. Int J Risk Saf Med. 2017;29(1-2):81-99. doi: 10.3233/JRS-170741. Int J Risk Saf Med. 2017. PMID: 28885222

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters